SEHK:9995Biotechs
Assessing RemeGen (SEHK:9995) Valuation After AbbVie RC148 Licensing Agreement
Why AbbVie’s RC148 licensing deal matters for RemeGen
RemeGen (SEHK:9995) moved into focus after AbbVie signed an exclusive licensing agreement for RC148, a PD-1/VEGF bispecific antibody. The deal grants AbbVie rights outside Greater China and secures sizeable upfront, milestone and royalty economics for RemeGen.
See our latest analysis for RemeGen.
RemeGen’s share price has responded sharply to the AbbVie announcement, with a 23.53% 1 month share price return and a very large 1 year total...